Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1681
    +0.0025 (+0.21%)
     

  • GBP/USD

    1.2495
    -0.0016 (-0.13%)
     

  • Bitcoin GBP

    51,239.52
    -538.03 (-1.04%)
     

  • CMC Crypto 200

    1,329.85
    -66.69 (-4.60%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CRUDE OIL

    83.68
    +0.11 (+0.13%)
     

  • GOLD FUTURES

    2,350.60
    +8.10 (+0.35%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Composition of the Nomination Committee of Orion Corporation

Orion Oyj
·2-min read
Orion Oyj
Orion Oyj

ORION CORPORATION
STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE
28 APRIL 2023 at 11.30 EEST

Composition of the Nomination Committee of Orion Corporation

The Board of Directors of Orion Corporation has appointed the following persons to the Nomination Committee of the company:

  • Annika Ekman

  • Petteri Karttunen

  • Minna Maasilta

  • Hilpi Rautelin

  • Seppo Salonen

  • Mikael Silvennoinen

Mikael Silvennoinen was appointed as Chair of the Committee.

The Committee prepares and presents a recommendation to the Board of Directors for the proposal to the Annual General Meeting concerning the composition of the Board.

ADVERTISEMENT

The essentials of the charter of the Nomination Committee and a description of the appointment process of its members are provided at https://www.orion.fi/en/investors/corporate-governance/board-of-directors/nomination-committee/charter-of-the-nomination-committee/, a page in the Corporate Governance section of the Orion Group website.

Orion Corporation

Liisa Hurme

President and CEO

   

Olli Huotari

SVP, Corporate Functions

 


Contact person:
Olli Huotari, SVP, Corporate Functions, Secretary to the Board of Directors of Orion Corporation
tel. +358 10 426 3054

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.